- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp stock price live, this page displays NYSE EW stock exchange data. View the EW premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Edwards Lifesciences Corp real time stock price chart below.
What Is the Edwards Lifesciences Corp Stock Price Today?
The Edwards Lifesciences Corp stock price today is 81.14.
What Is the Stock Symbol for Edwards Lifesciences Corp?
The stock symbol for Edwards Lifesciences Corp is "EW."
What Stock Exchange Does Edwards Lifesciences Corp Trade On?
Edwards Lifesciences Corp is listed and trades on the NYSE stock exchange.
Is Edwards Lifesciences Corp a Good Stock to Buy?
Determining whether Edwards Lifesciences Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EW quote. (ISIN: US28176E1082)
What Is the Edwards Lifesciences Corp Stock Price Today?
The Edwards Lifesciences Corp stock price today is 81.14.
What Is the Stock Symbol for Edwards Lifesciences Corp?
The stock symbol for Edwards Lifesciences Corp is "EW."
What Stock Exchange Does Edwards Lifesciences Corp Trade On?
Edwards Lifesciences Corp is listed and trades on the NYSE stock exchange.
Is Edwards Lifesciences Corp a Good Stock to Buy?
Determining whether Edwards Lifesciences Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EW quote. (ISIN: US28176E1082)
81.14
-1.62(-1.96%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
80.76
83.04
52 wk Range
72.30
87.89
EW is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
80.7683.04
52 wk Range
72.3087.89
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EW Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
97.15
Upside
+19.73%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
13 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
22 Buy
8 Hold
0 Sell
Ratings:
30 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 97.15
(+19.73% Upside)
Edwards Lifesciences Corp SWOT Analysis
Market Leadership | Edwards Lifesciences dominates the TAVR market with robust growth, while expanding into promising TMTT segment with ambitious $2 billion sales target by 2030 |
Financial Health | Strong financials with 79.5% gross margins and 8.23% revenue growth. Analysts project double-digit EPS growth and margin expansion from 2026 onwards |
Regulatory Catalysts | Potential NCD changes could significantly boost TAVR adoption. FDA approval for asymptomatic aortic stenosis treatment may drive market expansion |
Analyst Perspectives | Price targets range from $80 to $90, reflecting confidence in growth potential. Analysts highlight TMTT and new market segments as key drivers |
Edwards Lifesciences Corp Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $1.65B (up 12.7% YoY), beating estimates of $1.6B; adjusted EPS of $0.78 exceeded forecast of $0.73 by 6.85%.
- Strong performance driven by TAVR and TMTT product lines, with adjusted gross profit margin at 78.2% and cash reserves of $2.4B.
- Full-year 2026 sales growth guidance raised to 9%-11% from 8%-10%; adjusted EPS guidance increased to $2.95-$3.05 range.
- CEO Mussallem cited strategic investments and innovation as key drivers; stock rose 0.16% after-hours to $81.66 despite 2.15% regular session decline.
- Key risks include currency fluctuations, heightened structural heart market competition, supply chain disruptions, and regulatory changes in major markets.
Last Updated: 2026-04-23, 06:26 p/m
Read Full TranscriptEarnings
Latest Release
Apr 23, 2026
EPS / Forecast
0.78 / 0.73
Revenue / Forecast
1.65B / 1.6B
Compare EW to Peers and Sector
Metrics to compare | EW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEWPeersSector | |
|---|---|---|---|---|
P/E Ratio | 43.9x | 23.0x | −0.6x | |
PEG Ratio | −0.61 | 1.06 | 0.00 | |
Price/Book | 4.6x | 3.0x | 2.6x | |
Price / LTM Sales | 7.5x | 2.2x | 3.2x | |
Upside (Analyst Target) | 20.2% | 73.1% | 48.1% | |
Fair Value Upside | Unlock | 33.3% | 5.8% | Unlock |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Edwards Lifesciences (EW) Stock Price Today?
The Edwards Lifesciences stock price today is 81.14 USD.
What Stock Exchange Does Edwards Lifesciences Trade On?
Edwards Lifesciences is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Edwards Lifesciences?
The stock symbol for Edwards Lifesciences is "EW."
What Is the Edwards Lifesciences Market Cap?
As of today, Edwards Lifesciences market cap is 46.62B USD.
What Is Edwards Lifesciences's Earnings Per Share (TTM)?
The Edwards Lifesciences EPS (TTM) is 1.88.
When Is the Next Edwards Lifesciences Earnings Date?
Edwards Lifesciences will release its next earnings report on Jul 23, 2026.
From a Technical Analysis Perspective, Is EW a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Edwards Lifesciences Stock Split?
Edwards Lifesciences has split 3 times.
How Many Employees Does Edwards Lifesciences Have?
Edwards Lifesciences has 16000 employees.
What is the current trading status of Edwards Lifesciences (EW)?
As of May 08, 2026, Edwards Lifesciences (EW) is trading at a price of 81.14 USD, with a previous close of 82.76 USD. The stock has fluctuated within a day range of 80.76 USD to 83.04 USD, while its 52-week range spans from 72.30 USD to 87.89 USD.
What Is Edwards Lifesciences (EW) Price Target According to Analysts?
The average 12-month price target for Edwards Lifesciences is 97.15 USD, with a high estimate of 110 USD and a low estimate of 84 USD. 22 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +19.73% Upside potential.
What Is the EW Premarket Price?
EW's last pre-market stock price is 82.37 USD. The pre-market share volume is 120.00, and the stock has decreased by -0.39, or -0.47%.
What Is the EW After Hours Price?
EW's last after hours stock price is 82.70 USD, the stock has decreased by -0.06, or -0.07%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.